Sanavia Oncology
Biotechnology, 430 E 29th St, New York, 10016, United States, 11-50 Employees
Phone Number: +12*********
Who is SANAVIA ONCOLOGY
We are a New York-based biotech company with a team of drug developers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine and Columbia University....
Read More
-
Headquarters: 430 E 29th St, New York, New York, 10016, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from SANAVIA ONCOLOGY
Sanavia Oncology Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sanavia Oncology
Answer: Sanavia Oncology's headquarters are located at 430 E 29th St, New York, 10016, United States
Answer: Sanavia Oncology's phone number is +12*********
Answer: Sanavia Oncology's official website is https://sanavia.bio
Answer: Sanavia Oncology's revenue is $25 Million to $50 Million
Answer: Sanavia Oncology has 11-50 employees
Answer: Sanavia Oncology is in Biotechnology
Answer: Sanavia Oncology contact info: Phone number: +12********* Website: https://sanavia.bio
Answer: We are a New York-based biotech company with a team of drug developers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine and Columbia University. Majority of cancer patients do not benefit from currently available therapies due to drug resistance. We are developing novel immunotherapies that can safely and effectively overcome that drug resistance and improve patients' lives. We use our proprietary platform to discover clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes. We combine high throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence with novel in vivo models for validating our targets and developing next generation immunotherapies that can safely and effectively eliminate drug-resistant tumors.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month